Lisanti Capital Growth LLC Has $5.67 Million Holdings in Corcept Therapeutics Incorporated $CORT

Lisanti Capital Growth LLC increased its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 47.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 68,273 shares of the biotechnology company’s stock after purchasing an additional 21,913 shares during the quarter. Corcept Therapeutics makes up 1.4% of Lisanti Capital Growth LLC’s investment portfolio, making the stock its 25th biggest holding. Lisanti Capital Growth LLC owned approximately 0.06% of Corcept Therapeutics worth $5,674,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of CORT. Abacus FCF Advisors LLC acquired a new stake in shares of Corcept Therapeutics during the third quarter worth $3,238,000. Pacer Advisors Inc. lifted its holdings in Corcept Therapeutics by 6,796.7% in the third quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company’s stock valued at $32,459,000 after buying an additional 384,896 shares during the period. Cerity Partners LLC boosted its position in Corcept Therapeutics by 21.4% during the second quarter. Cerity Partners LLC now owns 746,593 shares of the biotechnology company’s stock valued at $54,800,000 after acquiring an additional 131,799 shares during the last quarter. Synergy Asset Management LLC grew its holdings in Corcept Therapeutics by 96.1% during the 3rd quarter. Synergy Asset Management LLC now owns 506,856 shares of the biotechnology company’s stock worth $39,615,000 after acquiring an additional 248,362 shares during the period. Finally, Ellsworth Advisors LLC bought a new position in shares of Corcept Therapeutics in the 3rd quarter worth about $769,000. 93.61% of the stock is owned by institutional investors.

Corcept Therapeutics Price Performance

Shares of CORT opened at $39.87 on Friday. The business’s fifty day moving average is $62.11 and its 200 day moving average is $70.17. Corcept Therapeutics Incorporated has a 12-month low of $32.99 and a 12-month high of $117.33. The company has a quick ratio of 3.07, a current ratio of 3.14 and a debt-to-equity ratio of 0.01. The stock has a market cap of $4.19 billion, a P/E ratio of 45.31 and a beta of 0.23.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). Corcept Therapeutics had a net margin of 14.19% and a return on equity of 15.99%. The business had revenue of $207.64 million for the quarter, compared to the consensus estimate of $223.78 million. During the same quarter last year, the firm posted $0.41 EPS. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. Sell-side analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Negative Sentiment: Corrected FDA letter shows agency warned Corcept multiple times not to file the relacorilant application, suggesting the submission may have been premature and increasing the likelihood of rejection or lengthy remediation — a direct hit to the drug’s approval outlook and commercial timeline. Read More.
• Negative Sentiment: Market coverage amplified the regulatory setback and its implications for relacorilant; media reports accelerated selling pressure and negative investor sentiment. Read More.
• Negative Sentiment: Multiple law firms have launched securities investigations and potential class‑action claims alleging Corcept may have misled investors about relacorilant or related disclosures; this increases legal and financial risk (possible settlements, defense costs, management distraction). Representative notices: Berman Tabacco, Rosen Law Firm, Bernstein Liebhard, Block & Leviton, Pomerantz, Schall, DJS. Read More. Read More. Read More.

Insider Buying and Selling at Corcept Therapeutics

In related news, CEO Joseph K. Belanoff sold 40,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $79.77, for a total value of $3,190,800.00. Following the transaction, the chief executive officer owned 2,701,370 shares of the company’s stock, valued at approximately $215,488,284.90. This trade represents a 1.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the transaction, the insider owned 1,235 shares of the company’s stock, valued at $43,447.30. This trade represents a 94.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 194,500 shares of company stock worth $14,186,410. 20.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on CORT shares. HC Wainwright upped their target price on Corcept Therapeutics from $90.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Zacks Research cut Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, October 18th. Finally, Canaccord Genuity Group raised their price target on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, January 23rd. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $83.50.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.